JP2022539091A5 - - Google Patents

Info

Publication number
JP2022539091A5
JP2022539091A5 JP2021577007A JP2021577007A JP2022539091A5 JP 2022539091 A5 JP2022539091 A5 JP 2022539091A5 JP 2021577007 A JP2021577007 A JP 2021577007A JP 2021577007 A JP2021577007 A JP 2021577007A JP 2022539091 A5 JP2022539091 A5 JP 2022539091A5
Authority
JP
Japan
Prior art keywords
aliphatic
independently
formula
pharmaceutically acceptable
heteroaliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021577007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539091A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/050660 external-priority patent/WO2020257870A1/en
Publication of JP2022539091A publication Critical patent/JP2022539091A/ja
Publication of JP2022539091A5 publication Critical patent/JP2022539091A5/ja
Priority to JP2025064409A priority Critical patent/JP2025108536A/ja
Pending legal-status Critical Current

Links

JP2021577007A 2019-06-26 2020-06-26 新規な分子 Pending JP2022539091A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064409A JP2025108536A (ja) 2019-06-26 2025-04-09 新規な分子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2019902231 2019-06-26
AU2019902231A AU2019902231A0 (en) 2019-06-26 Novel molecules
AU2019904862A AU2019904862A0 (en) 2019-12-20 Novel molecules (2)
AU2019904862 2019-12-20
PCT/AU2020/050660 WO2020257870A1 (en) 2019-06-26 2020-06-26 Novel molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064409A Division JP2025108536A (ja) 2019-06-26 2025-04-09 新規な分子

Publications (2)

Publication Number Publication Date
JP2022539091A JP2022539091A (ja) 2022-09-07
JP2022539091A5 true JP2022539091A5 (cg-RX-API-DMAC7.html) 2023-07-03

Family

ID=74059610

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577007A Pending JP2022539091A (ja) 2019-06-26 2020-06-26 新規な分子
JP2025064409A Pending JP2025108536A (ja) 2019-06-26 2025-04-09 新規な分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064409A Pending JP2025108536A (ja) 2019-06-26 2025-04-09 新規な分子

Country Status (12)

Country Link
US (1) US12017979B2 (cg-RX-API-DMAC7.html)
EP (1) EP3990428A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022539091A (cg-RX-API-DMAC7.html)
KR (1) KR20220050873A (cg-RX-API-DMAC7.html)
CN (2) CN121045535A (cg-RX-API-DMAC7.html)
AU (1) AU2020302839B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025630A8 (cg-RX-API-DMAC7.html)
CA (1) CA3142501A1 (cg-RX-API-DMAC7.html)
IL (1) IL289266B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021015961A (cg-RX-API-DMAC7.html)
NZ (1) NZ783377A (cg-RX-API-DMAC7.html)
WO (1) WO2020257870A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
IL275360B2 (en) 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
AU2021278377A1 (en) * 2020-05-26 2022-12-15 Ena Respiratory Pty Ltd Treatment of coronavirus
AU2021294603A1 (en) 2020-06-26 2022-12-15 Ena Respiratory Pty Ltd Branched lipid compounds
AU2022338350A1 (en) * 2021-09-02 2024-02-29 Ena Respiratory Pty Ltd Formulation

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039715D1 (de) 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
PT1284740E (pt) 2000-05-19 2008-07-09 Corixa Corp Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos
EP1382352A1 (de) 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
US7569225B2 (en) 2002-08-12 2009-08-04 The Council Of The Queensland Institute Of Medical Research Immunogenic lipopeptides comprising T-helper and B-cell epitopes
ES2535451T3 (es) 2002-08-12 2015-05-11 The Council Of The Queensland Institute Of Medical Research Nuevos lipopéptidos inmunógenos que comprenden epítopos de linfocitos T auxiliares y de linfocitos T citotóxicos (CTL)
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
US20060002941A1 (en) 2004-01-23 2006-01-05 Vievax Corp. Compositions comprising immune response altering agents and methods of use
WO2005079419A2 (en) 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
KR20070068460A (ko) 2004-10-18 2007-06-29 글로브이뮨 만성 c형 간염에 대한 효모계 치료
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
NZ556004A (en) 2004-12-21 2010-05-28 Vaxinnate Corp Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
EP1861426A4 (en) 2005-02-08 2008-11-12 Queensland Inst Med Res IMMUNOGENOUS MOLECULES
WO2006091591A1 (en) 2005-02-22 2006-08-31 The Regents Of The University Of California Methods of treating gastrointestinal inflammation
EP1787660A1 (en) * 2005-11-22 2007-05-23 GBF Gesellschaft für Biotechnologische Forschung mbH New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
WO2008085549A2 (en) 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
AU2014202674B2 (en) * 2007-05-04 2014-08-14 Marina Biotech, Inc. Amino acid lipids and uses thereof
EP2200638B1 (en) 2007-10-09 2016-03-16 The University of Melbourne Compositions for the transfection of cells
WO2009137103A2 (en) 2008-05-09 2009-11-12 Ourth Donald D Anti-cancer/anti-viral compounds and methods of use
US8728465B2 (en) 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
US20110171259A1 (en) 2008-09-05 2011-07-14 Martin Gagne Novel Compositions and Adjuvants
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
KR101856462B1 (ko) 2009-03-25 2018-05-10 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
GB0907989D0 (en) 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
EP2338521A1 (en) 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
EA031379B1 (ru) * 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
IN2014CN02581A (cg-RX-API-DMAC7.html) * 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
US20170274068A1 (en) 2014-09-12 2017-09-28 The University Of Melbourne Immunological reagent
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP2016216593A (ja) 2015-05-19 2016-12-22 株式会社リコー 反応材、熱交換器及びケミカルヒートポンプ
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
AU2018241248B2 (en) 2017-03-31 2025-01-23 Ena Respiratory Pty Ltd Treatment of respiratory infection with a TLR2 agonist
NL2018803B1 (en) * 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
EP3676250A4 (en) * 2017-08-30 2021-05-26 Auckland Uniservices Limited PEPTIDE CONJUGATES, CONJUGATION METHODS AND USES THEREOF
IL275360B2 (en) 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
WO2019119069A1 (en) 2017-12-21 2019-06-27 Ena Therapeutics Pty Ltd Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent
JP2022546806A (ja) 2019-09-04 2022-11-09 アクセリア オンコロジー ピーティーワイ リミテッド 癌免疫療法
WO2021042174A1 (en) 2019-09-04 2021-03-11 Ena Therapeutics Pty Ltd Cancer treatment
AU2021278377A1 (en) 2020-05-26 2022-12-15 Ena Respiratory Pty Ltd Treatment of coronavirus

Similar Documents

Publication Publication Date Title
JP2024170587A5 (cg-RX-API-DMAC7.html)
JP2024542260A5 (cg-RX-API-DMAC7.html)
JP2024542188A5 (cg-RX-API-DMAC7.html)
JP2019509280A5 (cg-RX-API-DMAC7.html)
JP2020169171A5 (cg-RX-API-DMAC7.html)
JP2021532784A5 (cg-RX-API-DMAC7.html)
JP2005523922A5 (cg-RX-API-DMAC7.html)
JP2020532534A5 (cg-RX-API-DMAC7.html)
JP2023504184A5 (cg-RX-API-DMAC7.html)
JP2005533040A5 (cg-RX-API-DMAC7.html)
JP2006515585A5 (cg-RX-API-DMAC7.html)
JP2023513658A5 (cg-RX-API-DMAC7.html)
JP2004509128A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2017523225A5 (cg-RX-API-DMAC7.html)
JP2007504235A5 (cg-RX-API-DMAC7.html)
JP2021516271A5 (cg-RX-API-DMAC7.html)
JP2022513775A5 (cg-RX-API-DMAC7.html)
JP2023538524A5 (cg-RX-API-DMAC7.html)
RU97113367A (ru) Производные нейраминовой кислоты, их получение и применение в медицине
JP2022546806A5 (cg-RX-API-DMAC7.html)
JP2017518363A5 (cg-RX-API-DMAC7.html)
JP2025509134A5 (cg-RX-API-DMAC7.html)
JP2024501120A5 (cg-RX-API-DMAC7.html)
JP2003528826A5 (cg-RX-API-DMAC7.html)